Acute toxicity of radiochemotherapy in rectal cancer patients: a risk particularly for carriers of the TGFB1 Pro25 variant.

[1]  C. Andreassen.  Searching for genetic determinants of normal tissue radiosensitivity--are we on the right track? , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  Alison M Dunning,et al.  No association between SNPs regulating TGF-β1 secretion and late radiotherapy toxicity to the breast: results from the RAPPER study. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  Christophe Hennequin,et al.  Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Martel,et al.  Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[6]  J. Monson,et al.  Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial , 2009, The Lancet.

[7]  J. Aigueperse,et al.  Specific signals involved in the long-term maintenance of radiation-induced fibrogenic differentiation: a role for CCN2 and low concentration of TGF-beta1. , 2008, American journal of physiology. Cell physiology.

[8]  T. Berg,et al.  Evaluation of the transforming growth factor beta1 codon 25 (Arg-->Pro) polymorphism in alcoholic liver disease. , 2008, Cytokine.

[9]  E. Deutsch,et al.  Gastrointestinal , Hepatobiliary and Pancreatic Pathology Essential Role of Plasminogen Activator Inhibitor Type-1 in Radiation Enteropathy , 2010 .

[10]  H. Ostrer,et al.  TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[11]  J. Curtis,et al.  The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer. , 2008, Lung cancer.

[12]  P. Paré,et al.  Transforming growth factor-beta1 polymorphisms, airway responsiveness and lung function decline in smokers. , 2007, Respiratory medicine.

[13]  C. Rödel,et al.  Integration of Novel Agents into Combined-Modality Treatment for Rectal Cancer Patients , 2007, Strahlentherapie und Onkologie.

[14]  M. Plumb,et al.  The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes , 2007, British Journal of Cancer.

[15]  R. V. van Domburg,et al.  The Impact of Transforming Growth Factor-&bgr;1 Gene Polymorphism on End-Stage Renal Failure After Heart Transplantation , 2006, Transplantation.

[16]  F. Lordick,et al.  Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Sempoux,et al.  Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  C. Datz,et al.  TGF-beta1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis. , 2005, Cytokine.

[19]  E. Urso,et al.  A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  A. Blakemore,et al.  Transforming Growth Factor-β1 SNPs: Genetic and Phenotypic Correlations in Progressive Kidney Insufficiency , 2005, Nephron Experimental Nephrology.

[21]  N. Brooks,et al.  Donor and recipient-transforming growth factor-beta 1 polymorphism and cardiac transplant-related coronary artery disease. , 2004, Transplant immunology.

[22]  Rainer Fietkau,et al.  Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.

[23]  B. Jaber,et al.  Transforming growth factor-beta 1 gene polymorphisms and cardiovascular disease in hemodialysis patients. , 2004, Kidney international.

[24]  H. Groen,et al.  Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  H. Kampinga,et al.  Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.

[26]  C. N. Coleman,et al.  CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.

[27]  U. Binswanger,et al.  Role of codon 10 and codon 25 polymorphisms on TGF-beta 1 gene expression and protein synthesis in stable renal allograft recipients. , 2002, Transplantation proceedings.

[28]  I. Nagtegaal,et al.  Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Martin,et al.  TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target? , 2000, International journal of radiation oncology, biology, physics.

[30]  W. Curran,et al.  Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. , 2000, International journal of radiation oncology, biology, physics.

[31]  M. Hauer-Jensen,et al.  Cellular sources of transforming growth factor-beta isoforms in early and chronic radiation enteropathy. , 1998, The American journal of pathology.

[32]  P. Hasleton,et al.  Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. , 1998, Transplantation.

[33]  J. Chavaudra,et al.  Dernières recommandations de l'ICRU pour la prescription, l'enregistrement et le compte rendu de la radiothérapie externe , 1998 .

[34]  Alan Agresti,et al.  Categorical Data Analysis , 2003 .

[35]  M. Piérart,et al.  Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group. , 2004, European journal of cancer.

[36]  T. Spector,et al.  Genetic control of the circulating concentration of transforming growth factor type beta1. , 1999, Human molecular genetics.

[37]  J. Coggle,et al.  Long-term expression of transforming growth factor TGF beta 1 in mouse skin after localized beta-irradiation. , 1996, International journal of radiation biology.